BRPI0512392A - composições contendo aequorina e uso da aequorina - Google Patents

composições contendo aequorina e uso da aequorina

Info

Publication number
BRPI0512392A
BRPI0512392A BRPI0512392-5A BRPI0512392A BRPI0512392A BR PI0512392 A BRPI0512392 A BR PI0512392A BR PI0512392 A BRPI0512392 A BR PI0512392A BR PI0512392 A BRPI0512392 A BR PI0512392A
Authority
BR
Brazil
Prior art keywords
aequorin
containing compositions
present
compositions
aquorine
Prior art date
Application number
BRPI0512392-5A
Other languages
English (en)
Inventor
Mark Y Underwood
Original Assignee
Quincy Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quincy Bioscience Llc filed Critical Quincy Bioscience Llc
Publication of BRPI0512392A publication Critical patent/BRPI0512392A/pt
Publication of BRPI0512392B1 publication Critical patent/BRPI0512392B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)

Abstract

COMPOSIçõES CONTENDO AEQUORINA E USO DA AEQUORINA. A presente invenção refere-se a composições contendo aequorina e métodos para seu uso na prevenção e/ou para aliviar sintomas e distúrbios relacionados ao desequilíbrio de cálcio são fornecidos pela presente invenção.
BRPI0512392-5A 2004-06-21 2005-06-21 Composição para impedir ou aliviar um sintoma ou distúrbio associado ao desequilíbrio de cálcio, e uso de aequorina BRPI0512392B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/872,795 2004-06-21
US10/872,795 US20060229243A1 (en) 2004-06-21 2004-06-21 Aequorin-containing compositions and methods of using same
PCT/US2005/021770 WO2006010004A2 (en) 2004-06-21 2005-06-21 Aequorin-containing compositions and methods of using same

Publications (2)

Publication Number Publication Date
BRPI0512392A true BRPI0512392A (pt) 2008-03-11
BRPI0512392B1 BRPI0512392B1 (pt) 2022-12-13

Family

ID=35785748

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0512392-5A BRPI0512392B1 (pt) 2004-06-21 2005-06-21 Composição para impedir ou aliviar um sintoma ou distúrbio associado ao desequilíbrio de cálcio, e uso de aequorina

Country Status (20)

Country Link
US (3) US20060229243A1 (pt)
EP (2) EP2545934B1 (pt)
JP (1) JP4971150B2 (pt)
KR (1) KR101213555B1 (pt)
CN (1) CN1997383B (pt)
AU (1) AU2005265266B2 (pt)
BR (1) BRPI0512392B1 (pt)
CA (1) CA2571542C (pt)
CY (1) CY1114307T1 (pt)
DK (1) DK1768691T3 (pt)
ES (1) ES2422173T3 (pt)
IL (1) IL180195A (pt)
MX (1) MXPA06015037A (pt)
NZ (1) NZ552274A (pt)
PL (1) PL1768691T3 (pt)
PT (1) PT1768691E (pt)
SG (1) SG153848A1 (pt)
SI (1) SI1768691T1 (pt)
WO (1) WO2006010004A2 (pt)
ZA (1) ZA200610688B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060229243A1 (en) * 2004-06-21 2006-10-12 Quincy Resource Group, Inc. Aequorin-containing compositions and methods of using same
GB0625678D0 (en) 2006-12-21 2007-01-31 Lux Biotechnology Ltd Composition and method for detection of demineralisation
WO2009114597A1 (en) * 2008-03-11 2009-09-17 Quincy Bioscience, Llc Apoaequorin-containing compositions and methods of using same
JP2010143860A (ja) * 2008-12-19 2010-07-01 Chisso Corp タンパク質の安定化剤
US20110130336A1 (en) * 2009-10-16 2011-06-02 Quincy Bioscience, Llc Method of treating ischemic injury using apoaequorin
US9316588B2 (en) * 2010-12-24 2016-04-19 Otsuka Pharmaceutical Co., Ltd. Bioassay method for detecting physiologically active substance
BR112014011630A2 (pt) * 2011-11-15 2017-06-27 Quincy Bioscience Llc composições e métodos para redução de lesões neuronais devido à isquemia
GB201700317D0 (en) 2017-01-09 2017-02-22 Calcivis Ltd Detection device
USD1042180S1 (en) 2020-05-28 2024-09-17 Calcivis Limited Dental detection device

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001240855A (ja) * 2000-03-01 2001-09-04 Masashi Sugimoto 生物発光方法及び発光物品
US6800492B2 (en) * 2000-06-01 2004-10-05 Institute Pasteur Chimeric GFP-aequorin as bioluminescent Ca++ reporters at the single cell level
AU2001268328A1 (en) * 2000-06-12 2001-12-24 University Of Maryland Biotechnology Institute Method of controlling the binding of calmyrin to presenilin
US20060229243A1 (en) * 2004-06-21 2006-10-12 Quincy Resource Group, Inc. Aequorin-containing compositions and methods of using same

Also Published As

Publication number Publication date
CA2571542C (en) 2014-08-19
EP2545934A1 (en) 2013-01-16
IL180195A (en) 2014-03-31
EP1768691B1 (en) 2013-05-22
BRPI0512392B1 (pt) 2022-12-13
ZA200610688B (en) 2007-12-27
US7671015B2 (en) 2010-03-02
MXPA06015037A (es) 2007-07-11
KR101213555B1 (ko) 2012-12-18
CN1997383A (zh) 2007-07-11
WO2006010004A3 (en) 2007-03-08
HK1109576A1 (en) 2008-06-13
SI1768691T1 (sl) 2013-07-31
PT1768691E (pt) 2013-06-20
US20100152117A1 (en) 2010-06-17
US20060229243A1 (en) 2006-10-12
CY1114307T1 (el) 2016-08-31
ES2422173T3 (es) 2013-09-09
JP4971150B2 (ja) 2012-07-11
CN1997383B (zh) 2011-01-05
EP2545934B1 (en) 2014-12-10
SG153848A1 (en) 2009-07-29
JP2008503581A (ja) 2008-02-07
AU2005265266B2 (en) 2011-05-12
KR20070070154A (ko) 2007-07-03
NZ552274A (en) 2010-06-25
PL1768691T3 (pl) 2013-09-30
EP1768691A2 (en) 2007-04-04
IL180195A0 (en) 2007-06-03
US20080287350A1 (en) 2008-11-20
EP1768691A4 (en) 2010-08-04
WO2006010004A2 (en) 2006-01-26
AU2005265266A1 (en) 2006-01-26
CA2571542A1 (en) 2006-01-26
DK1768691T3 (da) 2013-07-01

Similar Documents

Publication Publication Date Title
BRPI0618451A2 (pt) derivados de piridopirazina, seu uso, composição farmacêutica e estojo
ECSP067043A (es) Derivados de pirrolotriazina útiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogénesis
ECSP13012708A (es) Compuestos y su uso como inhibidores de bace
NO20092718L (no) Antagonist-anti-Notch 3-antistoffer og deres anvendelse i forebyggelsen og behandlingen av Notch 3-relaterte sykdommer
EA200970581A1 (ru) Кристаллическое твёрдое основание разагилина
BRPI0607279A2 (pt) composição compatìvel com fertilizante
CY1112790T1 (el) Χρηση μαγιας σεληνιου στην αντιμετωπιση της νοσου αλτσχαιμερ
CL2013001367A1 (es) Conjunto de composiciones nutricionales para lactantes y niños pequeños que comprende una primera composicion para lactantes de 0 a 6 meses, una segunda composicion para lactantes de 6 meses y 1 año, y una tercera composicion para niños pequeños de 1 a 2 años, donde la primera y segunda composicion comprenden probioticos difiriendo entre si por la cantidad y/o naturaleza de los mismos; y su uso para prevenir y/o tratar diarrea entre otros desordenes.
NO20074941L (no) Anvendelse av diosmetinforbindelser i behandlingen og forebyggingen av trombotiske patologier
BRPI0619153A8 (pt) derivados de 4-aminopirroltriazina substituída, e composição farmacêutica
BRPI0516483A (pt) preparo e uso de derivados de ácido bifenil-4-il-carbonilamino para o tratamento de obesidade
PL2228374T3 (pl) Mrówczan nebiwololu
EP1919302B8 (en) Food comprising silicon
TW200609888A (en) Liquid crystal composition for bistable liquid crystal devices
CR10099A (es) Inmunoglobulinas dirigidas contra nogo
NO20076515L (no) Hydantoinforbindelser
UY30591A1 (es) Crema para bebidas
AR065368A1 (es) Anticuerpos para moleculas de ige
BRPI0512392A (pt) composições contendo aequorina e uso da aequorina
GT200600520A (es) Agentes antibacterianos
CL2008003602A1 (es) Compuestos derivados de triazolotriazinas y triazolopirazinas sustituidas; composicion farmaceutica; y su uso en el tratamiento y/o profilaxis de trastornos hematologicos.
WO2006116221A3 (en) Therapeutic combinations for the treatment or prevention of psychotic disorders
NO20074528L (no) Substituerte pyrroler, sammensetninger, fremgangsmate for fremstilling og anvendelse av samme
PL1922128T3 (pl) Element do zmniejszania zawartości drobnego pyłu w powietrzu, za pomocą mchów i/lub porostów
ATE477797T1 (de) Zusammensetzung enthaltend magnolol und honokiol in synergistischen mengen

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/06/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.